Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Principles of Renal Function Measurement (Limitations of Gotch's Kt/V).

Bonert M, Saville BA.

Can J Kidney Health Dis. 2018 May 31;5:2054358118776020. doi: 10.1177/2054358118776020. eCollection 2018.

2.

BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.

Geer EB, Shafiq I, Gordon MB, Bonert V, Ayala A, Swerdloff RS, Katznelson L, Lalazar Y, Manuylova E, Pulaski-Liebert KJ, Carmichael JD, Hannoush Z, Surampudi V, Broder MS, Cherepanov D, Eagan M, Lee J, Said Q, Neary MP, Biller BMK.

Endocr Pract. 2017 Aug;23(8):962-970. doi: 10.4158/EP171787.OR. Epub 2017 Jun 14.

PMID:
28614003
3.

Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.

Trpkov K, Hes O, Agaimy A, Bonert M, Martinek P, Magi-Galluzzi C, Kristiansen G, Lüders C, Nesi G, Compérat E, Sibony M, Berney DM, Mehra R, Brimo F, Hartmann A, Husain A, Frizzell N, Hills K, Maclean F, Srinivasan B, Gill AJ.

Am J Surg Pathol. 2016 Jul;40(7):865-75. doi: 10.1097/PAS.0000000000000617.

PMID:
26900816
4.

Eosinophilic, Solid, and Cystic Renal Cell Carcinoma: Clinicopathologic Study of 16 Unique, Sporadic Neoplasms Occurring in Women.

Trpkov K, Hes O, Bonert M, Lopez JI, Bonsib SM, Nesi G, Comperat E, Sibony M, Berney DM, Martinek P, Bulimbasic S, Suster S, Sangoi A, Yilmaz A, Higgins JP, Zhou M, Gill AJ, Przybycin CG, Magi-Galluzzi C, McKenney JK.

Am J Surg Pathol. 2016 Jan;40(1):60-71. doi: 10.1097/PAS.0000000000000508.

PMID:
26414221
5.

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis.

Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S.

J Clin Endocrinol Metab. 2014 May;99(5):1825-33. doi: 10.1210/jc.2013-3757. Epub 2014 Feb 25.

6.

Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency.

Garcia JM, Swerdloff R, Wang C, Kyle M, Kipnes M, Biller BM, Cook D, Yuen KC, Bonert V, Dobs A, Molitch ME, Merriam GR.

J Clin Endocrinol Metab. 2013 Jun;98(6):2422-9. doi: 10.1210/jc.2013-1157. Epub 2013 Apr 4.

7.

Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.

Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S; SALSA Study Group.

Pituitary. 2010 Jun;13(2):115-22. doi: 10.1007/s11102-009-0207-x.

8.

Lipodystrophy in patients with acromegaly receiving pegvisomant.

Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S.

J Clin Endocrinol Metab. 2008 Sep;93(9):3515-8. doi: 10.1210/jc.2008-0833. Epub 2008 Jul 8.

PMID:
18611977
9.

Medical therapy: options and uses.

Carmichael JD, Bonert VS.

Rev Endocr Metab Disord. 2008 Mar;9(1):71-81. Review.

PMID:
18163211
10.
11.

A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.

Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A.

J Clin Endocrinol Metab. 2005 Jul;90(7):4405-10. Epub 2005 Apr 12.

PMID:
15827109
12.

Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.

Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A.

J Clin Endocrinol Metab. 2002 Apr;87(4):1692-9.

PMID:
11932303

Supplemental Content

Loading ...
Support Center